Eli Lilly loses share in India’s GLP‑1 market as cheap semaglutide generics surge, while Novo holds steady after deep price cuts to defend Ozempic, Wegovy.
Eli Lilly market share drops, Novo Nordisk holds firm as generic weight-loss drugs flood India